Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
NIPPON FELT surges to daily limit on first rebound in 6 days after DOE 5 Percent acquires over 5% stake
NIPPON FELT CO.,LTD. <3512> surged sharply for the first time in six days, reaching \1,018, up \150 from the previous trading day and temporarily hitting the daily price limit. After the close of trading on the 31st, it was revealed that DOE 5 Percent (Shibuya-ku, Tokyo), an investment firm, had newly acquired more than 5% of NIPPON FELT's shares, attracting speculative buying. According to the large shareholding report filed with the Kanto Local Finance Bureau, DOE 5 Percent and its joint holders own 5.01% of the company. The reporting obligation trigger date was March 24. The stated purpose of the holding is investment and enhancement of medium- to long-term corporate value through constructive dialogue, including the potential for significant proposal actions depending on circumstances.
Source: MINKABU PRESS
Related Articles
LIFEDRINK COMPANY Surges for Fourth Consecutive Day on Iris Ohyama Stake Increase to 7.7%
Asterisk shares continue sharp decline on TSE credit trading restrictions
Saikaya Department Store rebounds after 6-day decline on stronger-than-expected interim results amid gold price surge
TAIYO HOLDINGS shares fall sharply for fifth straight day as KKR launches tender offer at \4,750 per share for privatization
FX Summary: Yen strengthens to 158.40 range on buying triggered by BOJ Tankan survey
SONY GROUP Surges on Strategic Partnership with TCL in Home Entertainment
OKUWA's FY02/26 Results Fall Short of Guidance
AI-Driven Programs Ignite Volatile Market: Key Points for Tomorrow's Trading
LIFEDRINK COMPANY falls for first time in 5 days as profit-taking outweighs Iris Ohyama's consecutive stake increase reports
CHUGAI PHARMA extends gains as U.S. FDA approves Eli Lilly's oral obesity drug Founayo